This secondary kinase mutation results in a drug-resistant state of the cancer, where the actions of EGFR inhibitors are abrogated while its intrinsic EGFR kinase activity is maintained; this in turn contributes to ‘oncogenic drift’. This evidence concerns the gene EGFR and cancer.